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Leukemia is the most common childhood malignancy and acute lymphoblastic leukemia
(ALL) represents the largest sub-type. Despite remarkable improvements over the last
40 years, standard therapy fails in 10–20% of newly diagnosed patients. Survival for children
with relapsed ALL is poor, and the development and implementation of novel therapeu-
tic strategies in pediatric ALL are critical to further advancements. Immunotherapeutic
approaches have been central to more novel ALL therapies. However, more recent inno-
vation in antibody engineering has improved potency and efficacy, and antibody–drug
conjugates (ADCs) are an especially attractive option in severely immunocompromised
patients. An even more sophisticated antibody design is that of bi-specific T-cell engaging
or BiTE® antibodies, which directly recruit effector T cells to augment the anti-neoplastic
effect.This review focuses on blinatumomab, a bi-specific anti-CD19/CD3 antibody that has
shown efficacy in adult patients with precursor B-ALL and is currently being evaluated in
the pediatric setting.
Keywords: immunotherapy, acute lymphoblastic leukemia, pediatric leukemia, drug development, bi-specific
antibody,T-cell engager
INTRODUCTION
Leukemia is the most common childhood malignancy, of which
acute lymphoblastic leukemia (ALL) represents the largest sub-
type, accounting for nearly 75% of newly diagnosed cases. Despite
remarkable outcome improvement over the last 40 years, recent
data suggest that standard therapy fails in 10–20% of newly diag-
nosed patients (1), and given its incidence,ALL remains the leading
cause of cancer-related mortality under age 19 years (2). Survival
for children with relapsed ALL is poor, reaching only 15% in
those with early bone marrow relapse (3). While traditional salvage
regimens, which involve intensive combination chemotherapy fol-
lowed by allogeneic hematopoietic stem-cell transplant (HSCT),
may cure a small proportion, inability to achieve sustained remis-
sion, and concern for cumulative treatment-related morbidity
and mortality has prompted tremendous effort toward devel-
opment and implementation of novel therapeutic strategies in
pediatric ALL.
Increasing recognition of the heterogeneous mutational and
epigenetic landscape of pediatric ALL has centered many novel
therapeutic approaches on targeted molecular agents, as demon-
strated in Philadelphia-positive (Ph+) ALL. The prototype of
modern therapeutic advancement in this realm is the use of the
BCR-ABL kinase inhibitor, imatinib, in Ph+ALL, which has trans-
formed today’s treatment approach and dramatically improved
event-free survival in this leukemia sub-type (4). Despite this suc-
cess, clinical translation of most novel therapeutic targets is slow,
and development of resistance and up-regulation of escape path-
ways have proven formidable opponents to maintaining sustained
response to such agents.
Immunotherapeutic approaches have more recently come to
the forefront in ALL therapy. Given the reliability with which
leukemia cells express surface antigens not expressed on nor-
mal tissue, monoclonal antibodies are being widely investigated.
Unconjugated monoclonal antibodies, including rituximab (5, 6),
alemtuzumab (7), and epratuzumab (8), have demonstrated
utility in hematologic malignancies for several decades. However,
more recent innovation in antibody engineering has improved
potency and efficacy, including the creation of antibody–drug
conjugates (ADCs), which link antibodies to various chemother-
apeutics, radionucleotides, or toxins to enhance the cell killing
with less reliance on active host immunity, an especially attrac-
tive option in severely immunocompromised patients. An even
more sophisticated antibody design is that of bi-specific T-
cell engaging or BiTE® antibodies, which directly recruit effec-
tor T cells to augment the anti-neoplastic effect. Clinical use
of bi-specific antibodies was first reported in 1995 (9); since
that time, promising pre-clinical and early phase clinical work
in a variety of human cancers has fortified interest in these
constructs.
Key features of BiTE antibodies include the ability to redirect
target cell lysis via T-cells at sub-picomolar concentration, the abil-
ity to activate T-cells to kill in the presence of target cells, and the
ability to allow T-cells to lyse target cells in series (9). This chain
of events leads to a triggered activation of T-cells that stimulates
proliferation of CD4+ and CD8+ cytotoxic cells as long as target
cells are available. Bi-specificity for CD3, for which stimulation is
highly conditional, amplifies the T-cell signal (10, 11). Though T-
cell auto-reactivity might be anticipated as potential complication
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of BiTE therapy, to date, no autoimmune disorders have been
described in this context (10).
This review will focus on blinatumomab, a bi-specific anti-
CD19/CD3 antibody that has shown efficacy in adult patients
with precursor B-ALL (12) and is currently being evaluated in
the pediatric setting.
BLINATUMOMAB PHARMACOLOGY
Blinatumomab is a 55 kDa-fusion protein comprised of two single-
chain antibodies to CD19 and CD3, recombinantly joined by
a flexible, non-glycosylated five-amino acid non-immunogenic
linker that affords a very short distance between arms (10, 13, 14).
CD19 is an attractive target in malignancies of B-cell origin, given
its stable, nearly ubiquitous expression in B-cell malignancies (15).
Furthermore, CD19 holds proposed importance in sustaining the
malignant B-cell phenotype via mechanisms of proliferation, cell
survival, and self-renewal (16–18). The mechanistic advantage of
blinatumomab include its ability to draw malignant B-cells in close
proximity to CD3-positive T-cells without regard to T-cell receptor
(TCR) specificity or reliance on major histocompatibility com-
plex (MHC) class I molecules on the surface of antigen presenting
cells for activation. This non-specificity allows recruitment of a
polyclonal T-cell population (14, 19) and circumvents a known
mechanism of resistance to T-cell-based therapies through down-
regulation of MHC class molecules (20). Co-binding of CD19
and CD3 leads to T-cell activation, marked by up-regulation of
T-cell activation markers CD25, CD69, CD2, INFγ, TNFα, and
IL-2, -6, and -10 (21). Cell lysis is mediated by secretion of per-
forin and various granzymes stored in the secretory vesicles of
cytotoxic T-cells (22). In vitro data suggest that efficacy of bli-
natumomab is not compromised by low effector-to-target cell
ratios (14, 19) or dependent upon T-cells, which may be lim-
ited in number in heavily pre-treated patients (23). Additionally,
blinatumomab-activated T-cells appear to effectively induce serial
target cell killing, as seen on video-assisted microscopy (14).
PHARMACOKINETICS AND ADMINISTRATION OF
BLINATUMOMAB
Various schedules of blinatumomab administration have been
investigated, including short intravenous (IV) infusion that was
initially evaluated in a series of three adult phase I studies. Phar-
macokinetic (PK) profiling in these studies at dose levels ranging
from 0.75 to 13µg/m2 revealed a short half-life of approximately
2 h and provided further insight into the occurrence of serial lysis,
providing rationale for administration by continuous infusion
(24). PK analysis of continuous infusion blinatumomab in adult
patients with relapsed non-Hodgkin lymphoma (NHL) showed a
linear dose curve and predictable drug levels throughout, making
24-h infusion the preferred schedule of blinatumomab adminis-
tration. Though pediatric experience is limited, PK data from the
first phase I study of blinatumomab in children indicate similar
serum concentrations to those achieved in adults with attainment
of steady state concentration within 48 h of continuous infusion
(25, 26).
Given somewhat unique PK characteristics of blinatumomab,
there are certain practical requirements of administration. In cur-
rent clinical trials, blinatumomab is administered over a 28-day
continuous infusion, followed by a 14-day rest period. Shorter rest
periods between cycles have not been formally studied to date.
Multiple cycles of administration have been safely delivered. Based
on the side effect profile discussed below, hospital admission is cur-
rently required for close observation during treatment initiation,
depending on the extent of disease burden and the stage at which
patients are treated. Subsequently, with low disease burden and
after the peak period of side effects has passed, patients may be
discharged from hospital to continue treatment in the outpatient
setting.
SAFETY AND TOLERABILITY OF BLINATUMOMAB
Extensive pre-clinical characterization of blinatumomab, includ-
ing in vivo work in both mice (27) and chimpanzees (28) led
to first-in-human studies in 2001. A series of three adult phase
I studies evaluated blinatumomab given as a short IV infu-
sion at dose levels from 0.75 to 13µg/m2 in 21 patients with
relapsed/refractory NHL and one patient with chronic lympho-
cytic leukemia (CLL). The most commonly observed adverse
events (AEs) were pyrexia, rigors, and fatigue, of which most
were mild and all were reversible (24). More clinically pertinent
AEs involved CNS toxicities (including headache, aphasia, ataxia,
somnolence, tremor, disorientation, seizure), cytokine release syn-
drome (CRS), and leukopenia- and neutropenia-related infection,
which in the absence of objective responses, prompted early termi-
nation of these initial studies. A subsequent phase I dose-escalation
study of continuous administration blinatumomab showed simi-
lar AEs of pyrexia, chills, and leukopenia. However, at dose levels
up to 60µg/m2/day, CNS toxicity was less severe and CRS was not
observed, further supporting continuous infusion as the preferred
method of administration (29). After a dose finding run-in por-
tion, larger phase II studies in adult patients with minimal residual
disease positive (MRD+) ALL utilized a dose of 15µg/m2/day and
demonstrated toxicity profiles comparable to the ones in NHL
but with lower incidence of CNS toxicity in patients with MRD+
ALL after first line induction and consolidation (12). In patients
with relapsed/refractory ALL, the incidence of CNS toxicity and
CRS was higher than in patients with MRD+ ALL, in whom no
clinical CRS was observed (12, 30). Several current trials in adult
patients are exploring flat dosing of blinatumomab at 28µg/day.
In relapsed/refractory ALL, a pre-phase using a lower dose of bli-
natumomab is employed in an attempt to prevent or ameliorate
CRS prior to dose-escalation.
Preliminary data from the first and only pediatric phase I study
to date suggest substantial similarities among the pharmacologi-
cal, toxicity, and response profiles described in adults. This study,
which evaluates dose levels ranging from 5 to 30µg/m2/day in chil-
dren and adolescents with relapsed/refractory ALL, determined
a maximum tolerated dose (MTD) of 15µg/m2/day and a rec-
ommended dose of 5µg/m2/day in the first week, followed by
escalation to 15µg/m2/day beginning on day 8 and for all subse-
quent days of infusion (25, 26). There were two fatal dose-limiting
toxicities (DLTs) noted at higher dose levels (one CRS, one res-
piratory failure). Similar to adult studies, greater than 80% of
patients at all dose levels, including 86% of patients at the MTD
(n= 7), experienced AEs of grade 3 or higher. The most common
AEs at the MTD were pyrexia (100%), hypertension (71%), and
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headache (57%). Nervous system disorders, typically mild, were
common, occurring in 57% of patients at the MTD. However,
all five patients (100%) treated at 5µg/m2/day experienced some
degree of reversible neurologic toxicity, suggesting a non-linear
relationship. CRS was observed in 7 of 23 patients (30%) in this
study and was more common at higher dose levels and during the
first cycle of therapy, which likely correlates to larger disease bur-
den, as reported in adults (30). In light of the incidence and timing
of CRS, an altered blinatumomab dosing schedule of 5µg/m2/day
in the first week and 15µg/m2/day in the subsequent 3 weeks of
the first cycle was evaluated and determined to be safe and tolera-
ble in an expanded pediatric cohort of patients with ≥25% bone
marrow blasts. This dose is being evaluated in a phase II cohort
currently.
Though the majority of patients treated with blinatumomab
develop mild inflammatory symptoms related to T-cell activation
at initiation of therapy, CRS is a more severe condition charac-
terized by “flu-like” symptoms, such as fever, chills, and headache,
and the potential for hemodynamic instability, bleeding, capillary
leak syndrome, and respiratory compromise (31, 32). While symp-
tom severity varies, grade 3 or higher CRS has been observed in a
small percentage of adult patients (32). Release of inflammatory
cytokines IL-2, IL-6, IL-10, INFγ, and TNFα has been demon-
strated in adult and pediatric patients (31, 33). Data from the
recently completed phase I portion of the first pediatric study cor-
related early elevation and subsequent decline of inflammatory
cytokines with clinical symptoms of CRS, most particularly IL-6
and IL-10, and to a lesser degree INFγ (25, 26). The most recent
adult ALL study failed to associate degree of elevation of inflam-
matory cytokines to target B-cell frequency in the blood or bone
marrow (33) or to patient outcome (12). Acquisition and matura-
tion of additional pediatric data are necessary to further evaluate
this association in children.
To dampen the pro-inflammatory response associated with
blinatumomab therapy, current clinical trials mandate co-
administration of dexamethasone at the initiation of therapy,
which has been shown in cell culture experiments to effectively
reduce cytokine concentration without affecting T-cell activation
or the cytotoxic potential of blinatumomab against malignant B-
cells (21). An additional therapeutic option to negate more severe
symptoms of CRS is the IL-6 receptor antibody tocilizumab, which
recently showed clinical benefit in a pediatric patient with life-
threatening CRS (31). This addition to the therapeutic arsenal
offers an additional option for symptom control in patients with
very severe CRS that is not sufficiently managed with steroids.
CLINICAL EFFICACY OF BLINATUMOMAB
Efficacy of blinatumomab in B-cell driven malignancies was first
demonstrated in adult relapsed NHL. A dose-escalation phase I
study by Bargou et al. in 2008, reported “major response” in 11 of
38 patients, including 4 and 7 patients with complete and partial
responses, respectively (29). This study,which evaluated dose levels
from 0.5 to 90µg/m2/day, determined an MTD of 60µg/m2/day
in adults. However, in those with bone marrow involvement, doses
as low as 15µg/m2/day were effective, providing dosing ratio-
nale for the first study of blinatumomab in MRD+ precursor
B-cell ALL.
Minimal residual disease has emerged as perhaps the most
important prognostic factor in the majority of both pediatric
(34, 35) and adult (36) ALL cases. A phase II study by Topp
et al. evaluated the efficacy of blinatumomab at 15µg/m2/day
in 21 patients with MRD positive ALL (12). Of 20 evaluable
patients, 16 (80%) responded with negative MRD at the end
of the first cycle, including 12 patients who had persistent
MRD after previous induction and consolidation. Follow-up of
these patients showed 61% relapse-free survival at a median of
33 months (37).
A subsequent study evaluated response to blinatumomab in
relapsed/refractory precursor B-cell ALL (30). Though the initial
starting dose was 15µg/m2/day, as in the prior study, the dose
finding run-in part demonstrated a modified two-level dose of
5 and 15µg/m2/day for the first week and subsequent 3 weeks,
respectively, as the optimal dose based on increased toxicity (par-
ticularly CRS) in patients who received 15µg/m2/day throughout
the cycle. This dose was used for the Simon two-Stage part of the
trial. Complete response was observed in 25 of 36 patients (69%),
and of those, 22 of the 25 responders (88%) achieved MRD neg-
ative status (<10−4 cells by PCR). Response was higher amongst
those in first versus second or greater relapse.
In 2010, Handgretinger et al. described the first pediatric expe-
rience with blinatumomab in three children with multiply relapsed
precursor B-cell ALL following allogeneic HSCT (38). Complete
morphologic response with negative MRD was observed in all
patients after the first cycle of therapy, which consisted of 24 h con-
tinuous infusion blinatumomab at 15µg/m2/day for 4–6 weeks.
These responses in addition to compelling adult data prompted
initiation of the first phase I/II study of blinatumomab in chil-
dren, currently underway in Europe and North America through
the International Berlin–Frankfurt–Munster (iBFM) study group
and the Children’s Oncology Group (COG), respectively, which is
described above. Though limited within the context of a phase I
trial, published objective responses were noted in 43% of patients,
including partial response in 1 patient (4%) and complete mor-
phologic response with negative MRD (<10−4 cells detectable by
PCR) in 39% of patients. The phase II portion of this study to
more completely evaluate the efficacy and safety of this regimen
in children is on-going.
COMMENTARY AND CONCLUSION
The biologic complexity of pediatric ALL necessitates multifac-
eted therapeutic approaches. While the backbone of ALL therapy
remains cytotoxic chemotherapy with an ever-increasing role for
targeted molecular agents, blinatumomab is a new addition to the
arsenal against adult and pediatric ALL, in which integration of
immunotherapy stands to further improve outcomes in both the
upfront and relapsed settings. As experience with blinatumomab
in the setting of refractory and relapsed pediatric ALL continues
to grow, so does the level of comfort of managing the unique side
effect profile of this agent. What has yet to be defined is whether or
not there is a way to predict which patients will respond a priori,
whether or not abrogation of the cytokine release or pre-treatment
with steroids diminishes the efficacy in children, and whether or
not the degree of pre-treatment or specific or cumulative prior
therapies affects the potential for response. To date, some patients
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who have progressed on or following blinatumomab administra-
tion have gone on to chimeric antigen receptor (CAR) T-cell-based
therapies or other clinical trials with investigational agents. At
least one patient who did not respond to blinatumomab was able
to achieve remission with CAR-T cell administration (Personal
Communication, S. Grupp), although this has not been widely or
formally reported in the pediatric population to date. The optimal
placement of immunotherapy with blinatumomab and/or other
conventional and immune modulating approaches has yet to be
determined. Similarly, integration of blinatumomab into combi-
nation regimens will need to account for the unique toxicity profile
to ensure optimal safety for patients, as well as the best efficacy
potential.
Further clinical investigations to begin to answer some of these
questions and determine the optimal patient population, sequence
in therapy, and potential combination treatments will better elu-
cidate the possible role of blinatumomab in future treatment of
childhood ALL.
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